Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 39Squamous Cell Carcinoma of Head and Neck 20Lung Neoplasms 20Oropharyngeal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Endometrial Neoplasms 6Carcinoma 6Pancreatic Neoplasms 5Mouth Neoplasms 5Colorectal Neoplasms 5Cholangiocarcinoma 5Biliary Tract Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Laryngeal Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Squamous Cell 4Mesothelioma, Malignant 3Lymphoid Interstitial Pneumonia 3Hypopharyngeal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2

Interventions

Taxes 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Carboplatin 2Bevacizumab 2Platinum 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brenner Tumor × Cisplatin × 30 days × Clear all
NCT00951496 2026-06-02

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,560 enrolled 19 charts

Brenner Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡